Suppr超能文献

隐孢子虫的治疗:我们所知道的、存在的差距以及未来的方向。

Treatment of Cryptosporidium: What We Know, Gaps, and the Way Forward.

作者信息

Sparks Hayley, Nair Gayatri, Castellanos-Gonzalez Alejandro, White A Clinton

机构信息

Infectious Disease Division, Department of Internal Medicine, University of Texas Medical Branch Galveston, 301 University Boulevard, Route 0435, Galveston, TX 77555-0435 USA, TeL 1-409-747-0236, FAX 1-409-772-6527.

出版信息

Curr Trop Med Rep. 2015 Sep;2(3):181-187. doi: 10.1007/s40475-015-0056-9. Epub 2015 Aug 1.

Abstract

Cryptosporidiosis is increasingly recognized as an important global health concern. While initially reported in immunocompromised such as AIDS patients, cryptosporidiosis has now been documented as a major cause of childhood diarrhea and an important factor in childhood malnutrition. Currently, nitazoxanide is the only proven anti-parasitic treatment for infections. However, it is not effective in severely immunocompromised patients and there is limited data in infants. Immune reconstitution or decreased immunosuppression is critical to therapy in AIDS and transplant patients. This limitation of treatment options presents a major public health challenge given the important burden of disease. Repurposing of drugs developed for other indications and development of inhibitors for novel targets offer hope for improved therapies, but none have advanced to clinical studies.

摘要

隐孢子虫病日益被视为一个重要的全球健康问题。虽然最初是在免疫功能低下者(如艾滋病患者)中报道的,但隐孢子虫病现已被证明是儿童腹泻的主要原因以及儿童营养不良的一个重要因素。目前,硝唑尼特是唯一经证实可用于治疗隐孢子虫感染的抗寄生虫药物。然而,它对严重免疫功能低下的患者无效,且在婴儿中的数据有限。免疫重建或免疫抑制的降低对于艾滋病患者和移植患者的治疗至关重要。鉴于疾病的重要负担,治疗选择的这种局限性带来了重大的公共卫生挑战。将针对其他适应症开发的药物重新用于隐孢子虫病治疗以及开发针对新靶点的抑制剂为改进治疗带来了希望,但尚无药物进入临床研究阶段。

相似文献

1
Treatment of Cryptosporidium: What We Know, Gaps, and the Way Forward.
Curr Trop Med Rep. 2015 Sep;2(3):181-187. doi: 10.1007/s40475-015-0056-9. Epub 2015 Aug 1.
2
Treatment of cryptosporidiosis: nitazoxanide yes, but we can do better.
Expert Rev Anti Infect Ther. 2023 Feb;21(2):167-173. doi: 10.1080/14787210.2023.2160704. Epub 2022 Dec 26.
4
Cryptosporidiosis Drug Discovery: Opportunities and Challenges.
ACS Infect Dis. 2016 Aug 12;2(8):530-7. doi: 10.1021/acsinfecdis.6b00094. Epub 2016 Jul 22.
5
New drugs and treatment for cryptosporidiosis.
Curr Opin Infect Dis. 2004 Dec;17(6):557-64. doi: 10.1097/00001432-200412000-00008.
6
Widespread occurrence of Cryptosporidium infections in patients with HIV/AIDS: Epidemiology, clinical feature, diagnosis, and therapy.
Acta Trop. 2018 Nov;187:257-263. doi: 10.1016/j.actatropica.2018.08.018. Epub 2018 Aug 15.
7
Treatment of cryptosporidiosis: do we know what we think we know?
Curr Opin Infect Dis. 2010 Oct;23(5):494-9. doi: 10.1097/QCO.0b013e32833de052.
8
[Human cryptosporidiosis and Cryptosporidium spp. in Haiti].
Trop Med Int Health. 2006 Jun;11(6):929-34. doi: 10.1111/j.1365-3156.2006.01631.x.

引用本文的文献

1
Efficacy of nitazoxanide, ivermectin and albendazole in treatment of cryptosporidiosis in immunosuppressed mice.
J Parasit Dis. 2025 Jun;49(2):343-350. doi: 10.1007/s12639-024-01751-6. Epub 2024 Nov 7.
3
Editorial: Chemical-genetics to study microbial pathogen basis of infection and drug targets.
Front Cell Infect Microbiol. 2025 Mar 19;15:1582879. doi: 10.3389/fcimb.2025.1582879. eCollection 2025.
5
Effect of Nitazoxanide and Probiotic Treatment on Bangladeshi Children with Cryptosporidiosis.
Am J Trop Med Hyg. 2025 Feb 11;112(4):733-739. doi: 10.4269/ajtmh.23-0914. Print 2025 Apr 2.
6
Eugenol: effective complementary treatment for cryptosporidiosis in experimentally infected mice.
J Parasit Dis. 2024 Jun;48(2):370-380. doi: 10.1007/s12639-024-01676-0. Epub 2024 May 11.
7
Cryptosporidium parvum disrupts intestinal epithelial barrier in neonatal mice through downregulation of cell junction molecules.
PLoS Negl Trop Dis. 2024 May 24;18(5):e0012212. doi: 10.1371/journal.pntd.0012212. eCollection 2024 May.
8
9
and evaluation of the anti-cryptosporidial activity of eugenol.
Front Vet Sci. 2024 Mar 7;11:1374116. doi: 10.3389/fvets.2024.1374116. eCollection 2024.
10
Quercetin as a Promising Antiprotozoan Phytochemical: Current Knowledge and Future Research Avenues.
Biomed Res Int. 2024 Feb 29;2024:7632408. doi: 10.1155/2024/7632408. eCollection 2024.

本文引用的文献

2
Cryptosporidium infection after renal transplantation in an endemic area.
Transpl Infect Dis. 2015 Feb;17(1):48-55. doi: 10.1111/tid.12336. Epub 2015 Jan 12.
4
Target validation of the inosine monophosphate dehydrogenase (IMPDH) gene in Cryptosporidium using Phylomer(®) peptides.
Exp Parasitol. 2015 Jan;148:40-8. doi: 10.1016/j.exppara.2014.11.003. Epub 2014 Nov 20.
6
A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium.
Lancet Infect Dis. 2015 Jan;15(1):85-94. doi: 10.1016/S1473-3099(14)70772-8. Epub 2014 Sep 29.
7
Structural studies provide clues for analog design of specific inhibitors of Cryptosporidium hominis thymidylate synthase-dihydrofolate reductase.
Bioorg Med Chem Lett. 2014 Sep 1;24(17):4158-61. doi: 10.1016/j.bmcl.2014.07.049. Epub 2014 Jul 24.
8
Cryptosporidium species in humans and animals: current understanding and research needs.
Parasitology. 2014 Nov;141(13):1667-85. doi: 10.1017/S0031182014001085. Epub 2014 Aug 11.
9
Development and assessment of molecular diagnostic tests for 15 enteropathogens causing childhood diarrhoea: a multicentre study.
Lancet Infect Dis. 2014 Aug;14(8):716-724. doi: 10.1016/S1473-3099(14)70808-4. Epub 2014 Jul 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验